Reyon Pharmaceutical Co Ltd
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough … Read more
Reyon Pharmaceutical Co Ltd (102460) - Total Assets
Latest total assets as of September 2025: ₩473.11 Billion KRW
Based on the latest financial reports, Reyon Pharmaceutical Co Ltd (102460) holds total assets worth ₩473.11 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Reyon Pharmaceutical Co Ltd - Total Assets Trend (2008–2024)
This chart illustrates how Reyon Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Reyon Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Reyon Pharmaceutical Co Ltd's total assets of ₩473.11 Billion consist of 17.9% current assets and 82.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 2.0% |
| Accounts Receivable | ₩36.72 Billion | 7.3% |
| Inventory | ₩41.99 Billion | 8.4% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩4.60 Billion | 0.9% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Reyon Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Reyon Pharmaceutical Co Ltd's current assets represent 17.9% of total assets in 2024, a decrease from 75.6% in 2008.
- Cash Position: Cash and equivalents constituted 2.0% of total assets in 2024, down from 3.2% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is inventory at 8.4% of total assets.
Reyon Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Reyon Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Reyon Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Reyon Pharmaceutical Co Ltd generates 0.30x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Reyon Pharmaceutical Co Ltd generates $ 0.83 in net profit.
Reyon Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.60 | 0.63 | 2.42 |
| Quick Ratio | 0.34 | 0.34 | 1.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-53.78 Billion | ₩ -48.77 Billion | ₩ 69.02 Billion |
Reyon Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Reyon Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.91 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | ₩499.99 Billion |
| Market Capitalization | $20.74 Million USD |
Valuation Analysis
Below Book Valuation: The market values Reyon Pharmaceutical Co Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Reyon Pharmaceutical Co Ltd's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Reyon Pharmaceutical Co Ltd (2008–2024)
The table below shows the annual total assets of Reyon Pharmaceutical Co Ltd from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩499.99 Billion | +0.04% |
| 2023-12-31 | ₩499.78 Billion | +3.11% |
| 2022-12-31 | ₩484.69 Billion | +1.40% |
| 2021-12-31 | ₩477.98 Billion | +50.49% |
| 2020-12-31 | ₩317.61 Billion | +15.71% |
| 2019-12-31 | ₩274.48 Billion | -9.46% |
| 2018-12-31 | ₩303.17 Billion | +4.24% |
| 2017-12-31 | ₩290.84 Billion | +38.80% |
| 2016-12-31 | ₩209.54 Billion | +33.53% |
| 2012-12-31 | ₩156.92 Billion | +16.93% |
| 2011-12-31 | ₩134.20 Billion | +63.83% |
| 2009-12-31 | ₩81.91 Billion | +25.50% |
| 2008-12-31 | ₩65.27 Billion | -- |